Drug Treatment
-
{
- All
- News
- Videos
- Web Stories
-
Centre Puts Pain Drug Pregabalin Under Schedule H1 To Prevent Abuse
New Delhi, May 22 (IANS) Health Ministry on Friday said it has notified the inclusion of the drug ‘Pregabalin’ under Schedule H1 of the Drugs Rules, 1945. The decision has been taken in view of reports received from certain states regarding the misus
-
Killing 'Zombie Cells' Reverses Skin Ageing And Speeds Wound Healing, Reveals New Breakthrough Study
A new breakthrough study highlights that killing zombie cells could speed up wound healing and slow down skin ageing. Here is what the study found and how it may affect dermatology.
-
More Weight Loss While On Ozempic Means Lower Risk Of Obesity-Related Diseases, Says New Study
The new analysis suggests that greater weight loss achieved while taking Ozempic and similar GLP-1 medications may lead to a larger reduction in obesity-related disease risk.
-
Twisha Sharma Felt Acting "Not Her Cup Of Tea", Wanted To Study: Co-Star Dheekshithh Shetty
Twisha had worked in the Telugu film Mugguru Monagallu (2021) and the Hindi film Zara Sambhal Kay (2018) before venturing into the corporate world
-
Your Genes May Decide How Well Weight Loss Drugs Work: Study
The research suggested that some of the same gene variants associated with better weight loss were also linked to stronger gastrointestinal side effects such as nausea or vomiting.
-
7-Minute Cancer Shot Costing Rs 3.7 Lakh Per Dose Launched In India
The new injection uses a drug called atezolizumab, which works by blocking a protein called PD-L1. Cancer cells use this protein to hide from the immune system. Once the protein is blocked, the body's immune cells can identify and attack cancer cells
-
What I Tell Families When They Ask: Should We Put My Parent On The New Drug, Lormalzi?
Lormalzi is not a cure. I say this not to take away hope, but because understanding this is what allows families to make decisions rooted in reality rather than desperation.
-
Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks
Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explain who may benefit, who should avoid it, and the risks involved.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
Can Black Licorice Help Treat Inflammatory Bowel Disease? Researchers Say Yes
Scientists recently discovered that glycyrrhizin, a substance taken from black licorice root, may reduce inflammation and protect the intestines from damage caused due to IBD.
-
Weight Loss Drugs May Impact Brain's Reward Centre, Study Warns
Newer oral weight loss drugs could be doing more than only suppressing appetite -- they may also be directly altering brain circuits that control motivation and reward, according to a new study.
-
Rs 10 Crore Fake Medicine Racket Busted In Delhi, 4 Arrested
The gang specialized in faking high-stakes treatments for cancer, liver disease, and other critical illnesses, putting countless lives at risk across the country.
-
Assam Cop Shot In Anti-Drug Raid Near Manipur Border, Airlifted To Guwahati
Police said no arrests have been made so far, as the suspects escaped through the dense forest and the interstate border.
-
GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study
GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs.
-
Centre Puts Pain Drug Pregabalin Under Schedule H1 To Prevent Abuse
New Delhi, May 22 (IANS) Health Ministry on Friday said it has notified the inclusion of the drug ‘Pregabalin’ under Schedule H1 of the Drugs Rules, 1945. The decision has been taken in view of reports received from certain states regarding the misus
-
Killing 'Zombie Cells' Reverses Skin Ageing And Speeds Wound Healing, Reveals New Breakthrough Study
A new breakthrough study highlights that killing zombie cells could speed up wound healing and slow down skin ageing. Here is what the study found and how it may affect dermatology.
-
More Weight Loss While On Ozempic Means Lower Risk Of Obesity-Related Diseases, Says New Study
The new analysis suggests that greater weight loss achieved while taking Ozempic and similar GLP-1 medications may lead to a larger reduction in obesity-related disease risk.
-
Twisha Sharma Felt Acting "Not Her Cup Of Tea", Wanted To Study: Co-Star Dheekshithh Shetty
Twisha had worked in the Telugu film Mugguru Monagallu (2021) and the Hindi film Zara Sambhal Kay (2018) before venturing into the corporate world
-
Your Genes May Decide How Well Weight Loss Drugs Work: Study
The research suggested that some of the same gene variants associated with better weight loss were also linked to stronger gastrointestinal side effects such as nausea or vomiting.
-
7-Minute Cancer Shot Costing Rs 3.7 Lakh Per Dose Launched In India
The new injection uses a drug called atezolizumab, which works by blocking a protein called PD-L1. Cancer cells use this protein to hide from the immune system. Once the protein is blocked, the body's immune cells can identify and attack cancer cells
-
What I Tell Families When They Ask: Should We Put My Parent On The New Drug, Lormalzi?
Lormalzi is not a cure. I say this not to take away hope, but because understanding this is what allows families to make decisions rooted in reality rather than desperation.
-
Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks
Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explain who may benefit, who should avoid it, and the risks involved.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
Can Black Licorice Help Treat Inflammatory Bowel Disease? Researchers Say Yes
Scientists recently discovered that glycyrrhizin, a substance taken from black licorice root, may reduce inflammation and protect the intestines from damage caused due to IBD.
-
Weight Loss Drugs May Impact Brain's Reward Centre, Study Warns
Newer oral weight loss drugs could be doing more than only suppressing appetite -- they may also be directly altering brain circuits that control motivation and reward, according to a new study.
-
Rs 10 Crore Fake Medicine Racket Busted In Delhi, 4 Arrested
The gang specialized in faking high-stakes treatments for cancer, liver disease, and other critical illnesses, putting countless lives at risk across the country.
-
Assam Cop Shot In Anti-Drug Raid Near Manipur Border, Airlifted To Guwahati
Police said no arrests have been made so far, as the suspects escaped through the dense forest and the interstate border.
-
GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study
GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs.
